INVITATION TO ALL IN THE SICKLE CELL COMMUNITY!!!
INVITATION TO ALL IN THE SICKLE CELL COMMUNITY!!!
#SickleCellEducation
#PatientEmpowerment
Patients, Parents, Families, Support Groups, Sickle Cell NGOs, Sickle Cell Experts and ALL interested in the Sickle Cell cause,
You will agree that there is a great need for patient education around effective treatment and cure for Sickle Cell disease, engendering hope individually and collectively.
Sickle Cell Foundation Nigeria is collaborating with an organization aptly called “Putting Rare Diseases Patients First!”, to organize a WEBINAR on Sickle Cell tagged “SICKLE CELL DISEASE: ACCESSING THE NEW FRONTIER”.
THE AIM OF THE WEBINAR is to indeed open our eyes to “the New Frontier” because it is evident that the treatment of sickle cell has largely been focused on basically addressing symptoms. Of course, symptomatic treatment has its value and benefits, but there is need to key into and explore the New Frontier, which drives home the fact that Sickle Cell is a complex disease caused by A SINGLE GENETIC MUTATION, focusing on addressing this underlying mutation that leads to the symptomatic challenges of the disease.
The WEBINAR promises to be very informative and enlightening, providing ACTIONABLE INFORMATION; Patients and parents should be able to take the information received and do something with it; eg determine if they are potential candidates for ongoing clinical trials in Gene Therapy and Stem Cell transplantation (which they do not have to pay for).
Participants will also learn how to review the information available on ongoing clinical trials.
You are hereby warmly welcomed to the WEBINAR, details of which are as follows:
WEBINAR TITLE: Sickle Cell Disease: Accessing New Frontiers
TIME: 3:30pm GMT (4.30pm Nigerian time)
Date: Wednesday, 20th May 2020
Below and attached are the links and brochures for the programme.
Link to register
The presentation will be streamed on PRDPF!
FaceBook page Live
#SickleCellEducation
#PatientEmpowerment
Related posts
December 18, 2023
